FELIQS is a Japanese startup company funded with a total of $12 million to develop a portfolio of two patent-protected drug product candidates targeting two attractive multi-billion-dollar markets in ophthalmology and neonatology:
Retinopathy of prematurity (ROP) – FLQ-101, a lipid peroxidation inhibitor repurposed to prevent ROP. FLQ-101 will be in Phase I/II dosing in the US in 2025.
Age-related macular degeneration (AMD) – FLQ-105, proprietary lipid peroxidation and ferroptosis inhibitor for earlier intervention to treat AMD. FLQ-105 will be in the phase 1 study in 2026.
Each of these developmental candidates is identified through FELIQS’s proprietary screening platform targeting lipid peroxidation/ ferroptosis with proven efficacy from past prospective clinical trials.
Company Details
- Employees
- 4
- Address
- 1-1 Hyakunenkoen, Kurume,japan
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.feliqs.com/
- HQ
- KURUME
Feliqs Questions
Feliqs's website is https://www.feliqs.com/
Feliqs's LinkedIn profile is https://www.linkedin.com/company/feliqs
Feliqs has
4 employees.
View email and phone details for 4
employees at Feliqs.
Feliqs's industry is
Biotechnology Research
Feliqs's top competitors are
Aurion Biotech,
Onl Therapeutics,
Eyepoint,
Ocular Therapeutix, Inc.,
Oculogica,
Eyedaptic,
Ray Therapeutics, Inc.,
Lumithera, Inc.,
Optigo Biotherapeutics,
Oculis.
Feliqs's categories are Biotechnology Research
